Compare · GILD vs TWST
GILD vs TWST
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 20.4x TWST ($9.58B).
- Over the past year, GILD is up 27.2% and TWST is up 372.1% - TWST leads by 344.9 points.
- TWST has been more active in the news (14 items in the past 4 weeks vs 6 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 18 for TWST).
- Company
- Gilead Sciences Inc.
- Twist Bioscience Corporation
- Price
- $156.22-0.76%
- $132.87-7.91%
- Market cap
- $195.13B
- $9.58B
- 1M return
- +3.48%
- -14.56%
- 1Y return
- +27.19%
- +372.09%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2018
- News (4w)
- 6
- 14
- Recent ratings
- 25
- 18
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
Latest TWST
- SEC Form 4 filed by Twist Bioscience Corporation
- Jefferies initiated coverage on Twist Bioscience with a new price target
- SEC Form 4 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Twist Bioscience Corporation